Inhibition of NF-κB-mediated signaling by the cyclin-dependent kinase inhibitor CR8 overcomes prosurvival stimuli to induce apoptosis in chronic lymphocytic leukemia cells

Clinical Cancer Research

Volumn 19, Issue 9, 2013, Pages 2393-2405

  Cosimo, Emilio ^a   McCaig, Alison M ^a,c   Carter Brzezinski, Luke J M ^a   Wheadon, Helen ^a   Leach, Michael T ^b   Le Ster, Karine ^d   Berthou, Christian ^d   Durieu, Emilie ^e   Oumata, Nassima ^f   Galons, Hervé ^f,g   Meijer, Laurent ^e,f   Michie, Alison M ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GARTNAVEL GENERAL HOSPITAL   (United Kingdom)

^c ROYAL ALEXANDRA HOSPITAL   (United Kingdom)

^d BREST UNIVERSITY HOSPITAL   (France)

^e CNRS   (France)

^f ManRos Therapeutics   (France)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD19 ANTIGEN; CD3 ANTIGEN; CD40 LIGAND; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLIN DEPENDENT KINASE INHIBITOR CR8; FLAVOPIRIDOL; I KAPPA B ALPHA; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 4; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; PROTEIN KINASE ZAP 70; PROTEIN MCL 1; RNA POLYMERASE II; ROSCOVITINE; UNCLASSIFIED DRUG; X LINKED INHIBITOR OF APOPTOSIS;

ADULT; AGED; ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFICACY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SENSITIVITY; ENZYME ACTIVATION; ENZYME INHIBITION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; INTRACELLULAR SIGNALING; LEUKEMIA CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR MICROENVIRONMENT; UPREGULATION; WESTERN BLOTTING;

ADULT; AGED; ANTINEOPLASTIC AGENTS; APOPTOSIS; CD40 LIGAND; CELL CYCLE CHECKPOINTS; CELL PROLIFERATION; CELL SURVIVAL; CYCLIN-DEPENDENT KINASES; DRUG EVALUATION, PRECLINICAL; FEMALE; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; INHIBITORY CONCENTRATION 50; INTERLEUKIN-4; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; NF-KAPPA B; PROTO-ONCOGENE PROTEINS C-BCL-2; PURINES; PYRIDINES; RNA POLYMERASE II; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED; X-LINKED INHIBITOR OF APOPTOSIS PROTEIN;

EID: 84877087492     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2170     Document Type: Article

References (43)

1. Hallek M. State-of-the-art treatment of chronic lymphocytic leukemia. Hematol Am Soc Hematol Educ Program 2009;440-9.
2. Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S, et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998;91:3379-89. (Pubitemid 28193890)
3. Pepper C, Hoy T, Bentley P. Elevated Bcl-2/Bax are a consistent feature of apoptosis resistance in B-cell chronic lymphocytic leukaemia and are correlated with in vivo chemoresistance. Leuk Lymphoma 1998;28:355-61. (Pubitemid 28105041)
4. Messmer BT, Messmer D, Allen SL, Kolitz JE, Kudalkar P, Cesar D, et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukemia B cells. J Clin Invest 2005;115:755-64. (Pubitemid 40322252)
5. Herishanu Y, Pérez-Galán P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. Blood 2011;117:563-74.
6. Willimott S, Baou M, Naresh K, Wagner SD. CD154 induces a switch in pro-survival Bcl-2 family members in chronic lymphocytic leukaemia. Br J Haematol 2007;138:721-32. (Pubitemid 47313210)
7. Granziero L, Ghia P, Circosta P, Gottardi D, Strola G, Geuna M, et al. Survivin is expressed on CD40 stimulation and interfaces proliferation and apoptosis in B-cell chronic lymphocytic leukemia. Blood 2001;97:2777-83.
8. Smit LA, Hallaert DY, Spijker R, de Goeij B, Jaspers A, Kater AP, et al. Differential Noxa/Mcl-1 balance in peripheral versus lymph node chronic lymphocytic leukemia cells correlates with survival capacity. Blood 2007;109:1660-8. (Pubitemid 46242110)
9. Cuni S, Perez-Aciego P, Perez-Chacon G, Vargas JA, Sanchez A, Martin-Saavedra FM, et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004;18:1391-400. (Pubitemid 39136749)
10. Furman RR, Asgary Z, Mascarenhas JO, Liou HC, Schattner EJ. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000;164:2200-6. (Pubitemid 30108780)
11. Stilgenbauer S, Sander S, Bullinger L, Benner A, Leupolt E, Winkler D, et al. Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007;92:1242-5. (Pubitemid 350144184)
12. Balogh Z, Reiniger L, Rajnai H, Csomor J, Szepesi A, Balogh A, et al. High rate of neoplastic cells with genetic abnormalities in proliferation centers of chronic lymphocytic leukemia. Leuk Lymphoma 2011;52:1080-4.
13. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-66.
14. Byrd JC, Shinn C, Waselenko JK, Fuchs EJ, Lehman TA, Nguyen PL, et al. Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood 1998;92:3804-16. (Pubitemid 28525207)
15. Alvi AJ, Austen B, Weston VJ, Fegan C, MacCallum D, Gianella-Borradori A, et al. A novel CDK inhibitor, CYC202 (R-roscovitine), overcomes the defect in p53-dependent apoptosis in B-CLL by down-regulation of genes involved in transcription regulation and survival. Blood 2005;105:4484-91. (Pubitemid 40720798)
16. Chen R, Wierda WG, Chubb S, Hawtin RE, Fox JA, Keating MJ, et al. Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia. Blood 2009;113:4637-45.
17. Hahntow IN, Schneller F, Oelsner M, Weick K, Ringshausen I, Fend F, et al. Cyclin-dependent kinase inhibitor Roscovitine induces apoptosis in chronic lymphocytic leukemia cells. Leukemia 2004;18:747-55. (Pubitemid 38500193)
18. O'Brien S. New agents in the treatment of CLL. Hematol Am Soc Hematol Educ Program 2008;457-64.
19. Bettayeb K, Oumata N, Echalier A, Ferandin Y, Endicott JA, Galons H, et al. CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases. Oncogene 2008;27:5797-807.
20. Tang L, Li MH, Cao P, Wang F, Chang WR, Bach S, et al. Crystal structure of pyridoxal kinase in complex with roscovitine and derivatives. J Biol Chem 2005;280:31220-9. (Pubitemid 41291859)
21. Oumata N, Ferandin Y, Meijer L, Galons H. Practical synthesis of roscovitine and CR8. Org Process Res Dev 2009;13:641-4.
22. Oumata N, Bettayeb K, Ferandin Y, Demange L, Lopez-Giral A, Goddard ML, et al. Roscovitine-derived, dual-specificity inhibitors of cyclin-dependent kinases and casein kinases 1. J Med Chem 2008;51:5229-42.
23. McCaig AM, Cosimo E, Leach MT, Michie AM. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals. Br J Haematol 2011;153:199-211.
24. Riccardi C, Nicoletti I. Analysis of apoptosis by propidium iodide staining and flow cytometry. Nat Protoc 2006;1:1458-61.
25. Nakagawa R, Vukovic M, Cosimo E, Michie AM. Modulation of PKC-α promotes lineage reprogramming of committed B lymphocytes. Eur J Immunol 2012;42:1005-15.
26. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-delta delta C(T)) method. Methods 2001;25:402-408. (Pubitemid 34164012)
27. Hayden RE, Pratt G, Davies NJ, Khanim FL, Birtwistle J, Delgado J, et al. Treatment of primary CLL cells with bezafibrate and medroxyprogesterone acetate induces apoptosis and represses the proproliferative signal of CD40-ligand, in part through increased 15dDelta12,14,PGJ2. Leukemia 2009;23:292-304.
28. Hertlein E, Byrd JC. Signalling to drug resistance in CLL. Best Pract Res Clin Haematol 2010;23:121-31.
29. Tong WG, Chen R, Plunkett W, Siegel D, Sinha R, Harvey RD, et al. Phase I and pharmacologic study of SNS-032, a potent and selective Cdk2, 7, and 9 inhibitor, in patients with advanced chronic lymphocytic leukemia and multiple myeloma. J Clin Oncol 2010;28:3015-22.
30. Bettayeb K, Baunbæk D, Delehouze C, Loaëc N, Hole AJ, Baumli S, et al. CDK inhibitors roscovitine and CR8 trigger Mcl-1 down-regulation and apoptotic cell death in neuroblastoma cells. Genes Cancer 2010;1:369-80.
31. Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 2001;276:251-60. (Pubitemid 32050314)
32. Liu X, Shi S, Lam F, Pepper C, Fischer PM, Wang S. CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells when compared with flavopiridol. Int J Cancer 2012;130:1216-26.
33. Lin TS, Ruppert AS, Johnson AJ, Fischer B, Heerema NA, Andritsos LA, et al. Phase II study of flavopiridol in relapsed chronic lymphocytic leukemia demonstrating high response rates in genetically high-risk disease. J Clin Oncol 2009;27:6012-8.
34. Thomas LW, Lam C, Edwards W. Mcl-1; the molecular regulation of protein function. FEBS Lett 2010;584:2981-9.
35. Pepper C, Lin TT, Pratt G, Hewamana S, Brennan P, Hiller L, et al. Mcl-1 expression has in vitro and in vivo significance in chronic lymphocytic leukemia and is associated with other poor prognostic markers. Blood 2008;112:3807-17.
36. Awan FT, Kay NE, Davis ME, Wu W, Geyer SM, Leung N, et al. Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab. Blood 2009;113:535-7.
37. Natoni A, Murillo LS, Kliszczak AE, Catherwood MA, Montagnoli A, Samali A, et al. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells. Mol Cancer Ther 2011;10:1624-34.
38. Hewamana S, Alghazal S, Lin TT, Clement M, Jenkins C, Guzman ML, et al. The NF-kappaB subunit Rel A is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukemia and represents a promising therapeutic target. Blood 2008;111:4681-9.
39. Nowak DE, Tian B, Jamaluddin M, Boldogh I, Vergara LA, Choudhary S, et al. RelA Ser276 phosphorylation is required for activation of a subset of NF-kappaB-dependent genes by recruiting cyclin-dependent kinase 9/cyclin T1 complexes. Mol Cell Biol 2008;28:3623-38. (Pubitemid 351732900)
40. Dey A, Wong ET, Cheok CF, Tergaonkar V, Lane DP. R-Roscovitine simultaneously targets both the p53 and NF-kappaB pathways and causes potentiation of apoptosis: implications in cancer therapy. Cell Death Differ 2008;15:263-73.
41. Takada Y, Aggarwal BB. Flavopiridol inhibits NF-kappaB activation induced by various carcinogens and inflammatory agents through inhibition of IkappaBalpha kinase and p65 phosphorylation: abrogation of cyclin D1, cyclooxygenase-2, and matrix metalloprotease-9. J Biol Chem 2004;279:4750-9. (Pubitemid 38199070)
42. Leitch AE, Riley NA, Sheldrake TA, Festa M, Fox S, Duffi n R, et al. The cyclin-dependent kinase inhibitor R-roscovitine down-regulates Mcl-1 to override pro-in flammatory signalling and drive neutrophil apoptosis. Eur J Immunol 2010;40:1127-38.
43. Lanasa MC, Andritsos LA, Brown JR, Gabrilove J, Caligaris-Cappio F, Larson R, et al. Interim analysis of EFC6663, a multicenter phase 2 study of Alvocidib (flavopiridol), demonstrates clinical responses among patientswith fludarabine refractory CLL [abstract]. In: Proceedings of the 53rd ASH Annual Meeting and Exposition; 2010 Dec 5; Valencia, CA: Orange County Convention Center; 2010. Abstract nr 58.